| Type | Public |
| HQ | San Diego, US |
| Founded | 2002 |
| Size (employees) | 80 (est) |
| Website | cytori.com |
Cytori Therapeutics was founded in 2002 and is headquartered in San Diego, US
Report incorrect company information
Viewing summary data as a guest
Sign up for free to see all dataKey People/Management at Cytori Therapeutics
John K. Fraser
Chief Scientist
Marc H. Hedrick
President/CEO
Gregg A Lapointe
Director
Gary A. Lyons
Director
Ronald A. Martell
Director
Richard J. Hawkins
Chairman
Report incorrect company information
Cytori Therapeutics Office Locations
Cytori Therapeutics has offices in San Diego, San Antonio, Tokyo and Deeside
San Diego, (HQ)
3020 Callan Road
San Antonio,
12500 Network Blvd
Tokyo,
Otemachi Park Building 7F 1-1-1 Otemachi, Chiyoda-ku
Deeside,
Deeside Industrial Park East Unit 68, Third Avenue
Report incorrect company information
Cytori Therapeutics Financials and Metrics
Cytori Therapeutics Revenue
Cytori Therapeutics's revenue was reported to be $4.66 m in FY, 2016 which is a 3.8% decrease from the previous period.
| USD | |
|---|---|
Net income (Q3, 2018) | (2.3m) |
EBIT (Q3, 2018) | (1.5m) |
Market capitalization (16-Aug-2018) | 194.3k |
Closing stock price (16-Aug-2018) | 0.3 |
Cash (30-Sep-2018) | 6.8m |
Cytori Therapeutics's current market capitalization is $194.3 k.
Annual
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|---|
Revenue | 7.1m | 5.0m | 4.8m | 4.7m | |
Revenue growth, % | (30%) | (2%) | (4%) | ||
Cost of goods sold | 3.4m | 2.9m | 3.2m | 2.7m | |
Gross profit | 3.7m | 2.0m | 1.7m | 1.9m |
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales and marketing expense | 1.8m | 1.9m | 1.9m | 1.5m | 654.0k | 566.0k | 1.0m | 889.0k | 818.0k | 939.0k | 1.3m | 840.0k | 678.0k | 525.0k | 453.0k |
General and administrative expense | 4.3m | 4.3m | 4.6m | 4.2m | 2.8m | 2.4m | 2.3m | 2.3m | 2.0m | 2.1m | 2.1m | 1.8m | 2.2m | 1.5m | 1.5m |
R&D expense | 4.1m | 4.3m | 4.7m | 3.1m | 6.0m | 4.4m | 4.1m | 5.2m | 4.0m | 3.3m | 3.0m | 3.0m | 2.5m | 2.0m | 1.9m |
Operating expense total | 10.2m | 10.6m | 11.2m | 8.7m | (3.6m) | (22.0k) | 7.4m | 8.5m | 6.8m | 8.0m | 6.4m | 5.6m | 5.4m | 3.9m | 2.2m |
Annual
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 10.2m | 12.8m | 12.8m | 7.8m | 23.8m | 19.0m | 9.4m | 20.0m | 14.9m | 6.3m | 9.0m | 4.8m | 5.9m | 3.1m | 6.8m |
Inventories | 4.1m | 4.2m | 4.5m | 5.0m | 4.1m | 4.6m | 4.5m | 4.5m | 3.9m | 4.1m | 4.2m | 3.5m | 3.2m | 3.0m | 2.8m |
Current Assets | 18.1m | 22.1m | 20.5m | 14.6m | 29.7m | 26.0m | 16.5m | 26.8m | 21.0m | 12.1m | 15.6m | 9.8m | 10.7m | 7.4m | 10.8m |
PP&E | 1.2m | 1.3m | 1.6m | 1.9m | 1.7m | 1.5m | 1.4m | 1.3m | 3.6m | 3.4m | 3.3m | 2.9m | 2.8m | 2.6m |
Annual
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (16.1m) | (10.4m) | (22.2m) | (31.6m) | (17.5m) | (16.0m) | (5.3m) | (11.7m) | (17.1m) | (7.5m) | (13.6m) | (18.4m) | (4.4m) | (8.1m) | (10.4m) |
Depreciation and Amortization | 1.2m | 160.0k | 344.0k | 525.0k | 510.0k | 761.0k | 291.0k | 574.0k | 794.0k | 442.0k | 1.1m | 1.6m | 497.0k | 975.0k | 1.5m |
Inventories | (975.0k) | (551.0k) | (526.0k) | (1.2m) | 730.0k | (10.0k) | (206.0k) | (380.0k) | 190.0k | 7.0k | 159.0k | 457.0k | 141.0k | 371.0k | 615.0k |
Accounts Payable | (1.1m) | 351.0k | 124.0k | (666.0k) | 1.1m | 870.0k | 176.0k | (431.0k) | (1.0m) | (484.0k) | (194.0k) | (1.7m) | (556.0k) | (1.2m) | (1.3m) |
| USD | Y, 2018 |
|---|---|
Financial Leverage | 4.2 x |
Report incorrect company information
Cytori Therapeutics Online and Social Media Presence
2.3k Twitter followers
Cytori Therapeutics has 2.3k Twitter Followers. The number of followers has decreased 0.2% month over month and decreased 0.7% quarter over quarter
Report incorrect company information
Cytori Therapeutics News and Updates
October 30, 2018
Cytori Therapeutics Announces Receipt of Puregraft® Royalty Milestone
SAN DIEGO, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (Nasdaq: CYTX) announced today it has received a milestone payment of $1.0 million from Bimini Technologies, LLC (Bimini). The payment is a result of Bimini achieving the first $10.0 million in gross profits for previous divest…
August 31, 2018
Cytori Therapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
Presentation on Thursday, September 06, 2018 at 09:10 AM Eastern Time Presentation on Thursday, September 06, 2018 at 09:10 AM Eastern Time
Report incorrect company information
Cytori Therapeutics Company Life and Culture
Report incorrect company information
Cytori Therapeutics Frequently Asked Questions
When was Cytori Therapeutics founded?
Cytori Therapeutics was founded in 2002.
Who are Cytori Therapeutics key executives?
Cytori Therapeutics's key executives are John K. Fraser, Marc H. Hedrick and Gregg A Lapointe.
How many employees does Cytori Therapeutics have?
Cytori Therapeutics has 80 employees.
Who are Cytori Therapeutics competitors?
Competitors of Cytori Therapeutics include Sareum Holdings, ImmunoCellular Therapeutics and Seres Therapeutics.
Where is Cytori Therapeutics headquarters?
Cytori Therapeutics headquarters is located at 3020 Callan Road , San Diego.
Where are Cytori Therapeutics offices?
Cytori Therapeutics has offices in San Diego, San Antonio, Tokyo and Deeside.
How many offices does Cytori Therapeutics have?
Cytori Therapeutics has 4 offices.